



Supplementary Figure S1. Correlation matrix of eicosanoids. The scale indicates Pearson correlation coefficients on log-transformed data. Dark and light indicate positive and negative correlations, respectively. All 28 quantifiable metabolites are listed. Analyses revealed that eicosanoids within the same pathway (by class and substrate) tend to be positively correlated (white borders indicate strongest clusters). DHET, dihydroxyeicosatrienoic acid; DHOME, dihydroxyoctadecaenoic acid; DiHDPA, dihydroxydocosapentaenoic acid; DiHETE, dihydroxytetraenoic acid; EET, epoxyeicosatrienoic acid; EpDPE, epoxydocosapentaenoic acid; EpOME, epoxyoctadecaenoic acid; HETE, hydroxyeicosatetraenoic acid; HODE, hydroxyoctadecadienoic acids; PGF1 α , prostaglandin F1alpha; PGF2 α , prostaglandin F2alpha; TriHOME, trihydroxyoctadecenoic acid



Supplementary Figure S2. Expression of *CYP2J2* and *EPHX2* in peripheral blood mononuclear cells (PBMCs) across coronary artery disease (CAD) extent.

(a) mRNA levels of the cytochrome P450 epoxygenase *CYP2J2* in PBMCs were associated with CAD extent across no apparent CAD (N=30), nonobstructive CAD (N=30), and obstructive CAD (N=38) patients (ANOVA P=0.042). (b) In contrast, expression of the gene that encodes soluble epoxide hydrolase (*EPHX2*) was not associated with CAD extent (ANOVA P=0.320). Gene expression was normalized to *GAPDH* using the $2^{-\Delta Ct}$ method and log-transformed prior to analysis. Data presented as median (midline), interquartile range (box), and 95% confidence intervals (whiskers). *P<0.05 in unadjusted post-hoc pairwise comparisons using Fisher's LSD test.



Supplementary Table S1. Median free plasma concentrations of eicosanoid metabolites

Pathway	Analyte	Plasma Concentration (pg/mL)
AA – CYP epoxides	14,15-EET	299 (139)
	11,12-EET	163 (86)
	8,9-EET	197 (94)
	5,6-EET*	<LLOQ
AA – sEH diols	14,15-DHET	937 (433)
	11,12-DHET	594 (322)
	8,9-DHET	244 (150)
	5,6-DHET	253 (160)
AA – CYP hydroxyls	20-HETE	1,188 (762)
	19-HETE	646 (348)
AA – LOX metabolites	15-HETE	937 (503)
	12-HETE	63 (42)
	11-HETE	5,706 (3,600)
	8-HETE	12,628 (6,656)
	5-HETE	2,243 (1,759)
AA – COX metabolites	8-iso-PGF2 α	29 (12)
	6-keto-PGF1 α	51 (21)
	PGB2*	<LLOQ
	PGD2*	<LLOQ
	PGE2*	<LLOQ
	PGF2 α	238 (712)
	TXB2*	<LLOQ
LA – LOX metabolites	13-HODE	21,356 (11,200)
	9-HODE	15,222 (9,844)
	9,12,13-TriHOME	688 (798)
	9,10,13-TriHOME	9,150 (12,200)
LA – CYP epoxides	12,13-EpOME	1,714 (1,000)
	9,10-EpOME	4,200 (2,867)
LA – sEH diols	12,13-DHOME	2,809 (1,881)
	9,10-DHOME	1,742 (1,274)
EPA/DHA – epoxide/diols	19,20-DiHDPA	1,193 (706)
	17,18-DiHETE	2,794 (1,937)
	19,20-EpDPE	1,659 (1,019)
	17,18-EpETE*	<LLOQ

AA, arachidonic acid; COX, cyclooxygenase; CYP, cytochrome P450; DHA, docosahexaenoic acid; DHET, dihydroxyeicosatrienoic acid; DHOME, dihydroxyoctadecaenoic acid; DiHDPA, dihydroxydocosapentaenoic acid; DiHETE, dihydroxytetraenoic acid; EET, epoxyeicosatrienoic acid; EPA, eicosapentaenoic acid; EpDPE, epoxydocosapentaenoic acid; EpETE, epoxyeicosatetraenoic acid; EpOME, epoxyoctadecaenoic acid; HETE, hydroxyeicosatetraenoic acid; HODE, hydroxyoctadecadienoic acids; LA, linoleic acid; LOX, lipoxygenase; PGB2, prostaglandin B2; PGD2, prostaglandin D2; PGE2, prostaglandin E2; PGF1 α , prostaglandin F1alpha; PGF2 α , prostaglandin F2alpha; sEH, soluble epoxide hydrolase; TriHOME, trihydroxyoctadecenoic acid; TXB2, thromboxane B2.

Data presented as median (interquartile range).

*Analytes with >50% of the values falling below lower limit of quantification (LLOQ) were not included